Latest market price
18.15
-0.55-2.94%
TA
Loading chart...
Snapshot
| Index | — | P/E | 31.84 | EPS (ttm) | 0.57 | Insider Own | — | Shs Outstand | 285.17M | Perf Week | 0.28% |
| Market Cap | 5.18B | Forward P/E | 16.89 | EPS next Y | 1.07 | Insider Trans | -17.59% | Shs Float | 154.14M | Perf Month | 0.17% |
| Enterprise Value | 7.09B | PEG | 3.59 | EPS next Q | 0.27 | Short Float | 10.44% | Perf Quarter | 0.89% | ||
| Income | 164.00M | P/S | 4.26 | EPS this Y | 17.31% | Short Ratio | 6.66 | Perf Half Y | 17.10% | ||
| Sales | 1.22B | P/B | 7.77 | EPS next Y | 9.23% | ROA | 4.94% | Short Interest | 16.09M | Perf YTD | 2.89% |
| Book/sh | 2.34 | P/C | 14.50 | EPS next 5Y | 8.88% | ROE | 26.75% | 52W High | 19.85 -8.56% | Perf Year | 9.47% |
| Cash/sh | 1.25 | P/FCF | 46.21 | EPS past 3/5Y | — | ROIC | 8.80% | 52W Low | 13.09 38.66% | Perf 3Y | 42.91% |
| Dividend Est. | — | EV/EBITDA | 13.32 | Sales past 3/5Y | 5.05% 7.31% | Gross Margin | 54.72% | Volatility | 2.67% 2.88% | Perf 5Y | -30.19% |
| Dividend TTM | — | EV/Sales | 5.83 | EPS Y/Y TTM | 580.62% | Oper. Margin | 36.24% | ATR (14) | 0.50 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.53 | Sales Y/Y TTM | 8.10% | Profit Margin | 13.44% | RSI (14) | 47.94 | Recom | 2.17 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.80 | EPS Q/Q | 30.00% | SMA20 | 0.11% | Beta | 1.92 | Target Price | 21.33 |
| Payout | 0.00% | Debt/Eq | 3.41 | Sales Q/Q | 9.18% | SMA50 | -2.00% | Rel Volume | 1.51 | Prev Close | 18.70 |
| Employees | 3,000 | LT Debt/Eq | 3.37 | Earnings | Nov 03 | SMA200 | 6.75% | Avg Volume | 2.29M | Price | 18.15 |
| IPO Date | Nov 20, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 8.84% 3.77% | Net Debt/EBITDA | 3.59 | Volume | 3,452,027 | Change | -2.94% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-14-26 | Downgrade | JP Morgan | Neutral → Underweight | |
| Sep-08-26 | Reiterated | Piper Sandler | Overweight | $24 → $25 |
| Jun-24-26 | Reiterated | UBS | $18 → $19 | |
| Jun-05-26 | Reiterated | Goldman Sachs | Buy | $17 → $20 |
| Apr-14-26 | Reiterated | Barclays | Overweight | $20 → $18 |
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight | $17 → $24 |
| Jan-08-26 | Reiterated | RBC Capital | Outperform | $17 → $24 |
| Nov-05-25 | Reiterated | Barclays | Overweight | $19 → $20 |
| Nov-05-25 | Reiterated | Piper Sandler | Neutral | $13 → $17 |
| Oct-02-25 | Reiterated | Barclays | Overweight | $17 → $19 |
Latest News· Times ET
Oct-28-26
Oct-21-26
Oct-19-26
Oct-09-26
Sep-24-26
Sep-24-2604:16AM
Sep-18-26
Sep-18-2602:45PM
Sep-15-26
Sep-09-26
Sep-09-2612:57PM
Sep-08-26
Sep-08-2603:56AM
Aug-27-26
Aug-26-26
Aug-26-2606:13AM
Aug-25-26
Aug-25-2604:16AM
Aug-21-26
Aug-21-2602:29AM
Aug-20-26
03:24AM
Company
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,215 | 1,164 | 1,100 | 1,049 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 551 | 518 | 498 | 472 | — | — | — | — | — | |
| Gross Profit | 666 | 646 | 602 | 577 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 246 | 253 | 243 | 237 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | -22 | 0 | 62 | 63 | — | — | — | — | — | |
| Operating Income | 441 | 393 | 298 | 277 | — | — | — | — | — | |
| Interest Expense | 143 | 156 | 165 | 143 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -33 | -90 | -19 | -28 | — | — | — | — | — | |
| Net Income Before Taxes | 264 | 148 | 114 | 106 | — | — | — | — | — | |
| Income Taxes | 101 | 70 | 69 | 55 | — | — | — | — | — | |
| Consolidated Net Income | 164 | 78 | 44 | 51 | — | — | — | — | — | |
| Net Income From Continuing Operations | 164 | 78 | 44 | 51 | — | — | — | — | — | |
| Net Income | 164 | 78 | 44 | 51 | — | — | — | — | — | |
| EPS (Recurring) | 0.57 | 0.27 | 0.16 | 0.18 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.57 | 0.27 | 0.16 | 0.18 | — | — | — | — | — | |
| EPS (Diluted) | 0.57 | 0.27 | 0.16 | 0.18 | — | — | — | — | — | |
| EBITDA | 532 | 442 | 442 | 407 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 31.84 | 65.33 | 85.50 | 93.61 | — | — | — | — | — | |
| Price To Sales Ratio | 4.27 | 4.30 | 3.52 | 4.51 | — | — | — | — | — | |
| Gross Margin | 54.81 | 55.50 | 54.73 | 55.00 | — | — | — | — | — | |
| Operating Margin | 36.30 | 33.76 | 27.09 | 26.41 | — | — | — | — | — | |
| Net Margin | 13.50 | 6.70 | 4.00 | 4.86 | — | — | — | — | — | |
| Shares Outstanding | 286 | 284 | 283 | 281 | — | — | — | — | — | |
| Market Capitalization | 5,191 | 5,010 | 3,871 | 4,735 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Petras Michael B. Jr. | Executive Chairman | Aug 17 '26 | Sale | 18.50 | 1,144,515 | 21,174,786 | 397,912 | Aug 19 |
| Rutz Michael P | President of Sterigenics | Aug 07 '26 | Sale | 18.84 | 150,000 | 2,825,250 | 334,279 | Aug 11 |
| GTCR INVESTMENT XI LLC | Director, 10% Owner | May 13 '26 | Sale | 15.17 | 12,735,301 | 193,169,046 | 0 | May 15 |
| WARBURG PINCUS & CO. | Director, 10% Owner | May 13 '26 | Sale | 15.17 | 19,102,952 | 289,753,576 | 0 | May 15 |
| WARBURG PINCUS & CO. | Director, 10% Owner | Mar 06 '26 | Sale | 15.27 | 15,000,000 | 229,050,000 | 19,102,952 | Mar 10 |
| GTCR INVESTMENT XI LLC | Director, 10% Owner | Mar 06 '26 | Sale | 15.27 | 10,000,000 | 152,700,000 | 12,735,301 | Mar 10 |
| Petras Michael B. Jr. | Chairman & CEO | Mar 02 '26 | Option Exercise | 0.00 | 89,686 | 0 | 570,835 | Mar 04 |
| DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Mar 02 '26 | Option Exercise | 0.00 | 16,816 | 0 | 343,600 | Mar 04 |
| Lyons Jonathan M. | Sr. Vice President, CFO | Mar 02 '26 | Option Exercise | 0.00 | 17,937 | 0 | 201,493 | Mar 04 |
| Rutz Michael P | President of Sterigenics | Mar 02 '26 | Option Exercise | 0.00 | 14,573 | 0 | 456,553 | Mar 04 |
| Petras Michael B. Jr. | Chairman & CEO | Dec 08 '25 | Sale | 16.45 | 750,000 | 12,337,499 | 0 | Dec 10 |
| WARBURG PINCUS & CO. | Director, 10% Owner | Dec 03 '25 | Sale | 16.33 | 9,720,000 | 158,727,600 | 34,102,952 | Dec 05 |
| GTCR INVESTMENT XI LLC | Director, 10% Owner | Dec 03 '25 | Sale | 16.33 | 6,480,000 | 105,818,400 | 22,735,301 | Dec 05 |
| WARBURG PINCUS & CO. | Director, 10% Owner | Nov 10 '25 | Sale | 15.65 | 18,000,000 | 281,718,000 | 43,822,952 | Nov 12 |
| GTCR INVESTMENT XI LLC | Director, 10% Owner | Nov 10 '25 | Sale | 15.65 | 12,000,000 | 187,812,000 | 29,215,301 | Nov 12 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.